NEWS & MEDIA
Osteo-Pharma today announced that it has successfully obtained MREC approval for testing their lead product, OsteoActivator-P, in patients. OsteoActivator-P is a novel coated porcine collagen barrier membrane that will be placed on a dental defect to improve early bone formation.
Successful Preclinical Dental defect study Demonstrates Enhanced Bone Regeneration Properties of OsteoActivator coated collagen membranes
Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, today has announced that it has successfully completed a large preclinical study in mini-pigs, which shows its OsteoActivator coated collagen membranes to effectively promote new bone formation.
Osteo-Pharma Receives Notice of Intention to Grant the New Composition of Matter Patent Covering OsteoActivator® Formulations
Osteo-Pharma BV announced today that it received formal notice that the European Patent Office’s Examining Division issued the formal notification of intention to grant the Osteo-Pharma patent application titled “Compositions and products for use...
Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-stage pre-clinical development for various projects and will start its first dental clinical trial in mid-2021.